Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis.

Yu, Zongliang; Hu, Lanqing; Sun, Changxin; Wang, Zeping; Zhang, Xiaonan; Wu, Min; Liu, Longtao

Yu, Zongliang; Hu, Lanqing; Sun, Changxin; Wang, Zeping; Zhang, Xiaonan; Wu, Min; Liu, Longtao.

Afiliação

Yu Z; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hu L; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Sun C; Graduate School of Beijing University of Chinese Medicine, Beijing, China; and.
Wang Z; Graduate School of Beijing University of Chinese Medicine, Beijing, China; and.
Zhang X; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Wu M; Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liu L; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

J Cardiovasc Pharmacol ; 81(6): 445-453, 2023 06 01.

Article em En | MEDLINE | ID: mdl-36972559

Assuntos

Anticolesterolemiantes; Pró-Proteína Convertase 9; Humanos; Inibidores de PCSK9; Lipoproteína(a); Metanálise em Rede; Subtilisinas; Anticolesterolemiantes/efeitos adversos; Ensaios Clínicos Controlados Aleatórios como Assunto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: J Cardiovasc Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google